Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Dedicated

- PMLiVE

Bayer wins new Eylea approval in Europe

Macular oedema indication will provide more competition for Novartis’ Lucentis

- PMLiVE

AZ’s olaparib enters phase III for ovarian cancer

Development of the drug had previously been halted in 2011

Novartis building

Novartis wins childhood arthritis indication for Ilaris in EU

EC gives green light to drug for the treatment of systemic juvenile idiopathic arthritis

- PMLiVE

Roche’s Torsten Hoffmann to join Zealand Pharma

Joins the Danish biotech as chief scientific officer

- PMLiVE

GSK melanoma therapy Tafinlar cleared in EU

Follows approvals for skin cancer drug in US, Canada and Australia

Novartis day

More data backs Novartis’ serelaxin in heart failure

European Society of Cardiology (ESC) meeting told of significant additional benefits

- PMLiVE

Amgen drug misses endpoint in acute heart failure trial

Company pledges to pursue development of omecamtiv mecarbil in chronic heart failure

- PMLiVE

Lundbeck still ‘appalled’ by EC’s €94m anti-competition fine

Will appeal, but doesn't expect a quick decision

- PMLiVE

Saatchi & Saatchi Health relaunches Roche’s cancer website

Agency’s Madrid office redesigns site to provide information about colon cancer

- PMLiVE

ABPI appoints new head of media

Lisa Potter to join from NHS Direct

Bayer symbol

Bayer among most respected brands in US

Pharma giant among strongest contenders in BrandPower ranking

- PMLiVE

The evolution of IQWiG in Germany’s drug pricing policy

Over the past ten years Germany has created a well-oiled machine designed to ensure that it gets the best deal when it comes to drug prices

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links